Drug intelligence / Profile preview

OD-PHOENIX

Development stage: Phase 2
Lead developer: TBF Génie Tissulaire
Modality: Stem Cell Therapies → Cell Therapies, Other Cell Types → Cell Therapies, Adoptive Cell Transfer → Cell Therapies
Administration: Surgical Implantation

Overview

OD-PHOENIX is a decellularized, freeze-dried, irradiated osteochondral allograft developed by TBF Genie Tissulaire. It is designed to treat osteochondral lesions in joints, such as the talus and knee, by providing a processed allogeneic osteochondral material for implantation. This approach aims to avoid the need for autograft material harvesting from the patient's own body.

Beyond the preview

Go deeper on OD-PHOENIX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OD-PHOENIX.

Explore the full profile